GSK’s momelotinib receives orphan drug status for VEXAS syndrome

GSK’s momelotinib receives orphan drug status for VEXAS syndrome

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.